848591-86-6

Basic information

• Product Name: 5-BENZYL-TETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE
• Synonyms: 5-BENZYL-TETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE;5-Benzyl-octahydropyrrolo[3,4-c]pyrrole-1,3-dione;tetrahydro-5-(phenylmethyl)-pyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione
• CAS NO: 848591-86-6
• Molecular Formula: C₁₃H₁₄N₂O₂
• Molecular Weight: 230.26246
• Mol File: 848591-86-6.mol

Chemical Properties

• Boiling Point: 416.3±38.0 °C(Predicted)
• Appearance: /
• Density: 1.269±0.06 g/cm3(Predicted)
• PKA: 11.37±0.20(Predicted)
• CAS DataBase Reference: 5-BENZYL-TETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BENZYL-TETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE(848591-86-6)
• EPA Substance Registry System: 5-BENZYL-TETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE(848591-86-6)

Safety Data

• Hazardous Substances Data: 848591-86-6(Hazardous Substances Data)

Upstream product

• 541-59-3 maleiimide 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 165893-99-2 2,5-dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione 
• 123-56-8 Succinimide 
• 866319-12-2 2-acetyl-5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione 

Downstream Products

• 86732-22-1 2-benzyloctahydropyrrolo[3,4-c]pyrrole 
• 186202-73-3 tert-butyl 5-benzylhexahydropyrrolo[3.4-c]pyrrole-2(1H)-carboxylate 
• 141449-85-6 tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438080-43-3 tert-butyl 5-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438072-41-3 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438072-47-9 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)quinazolin-4-amine 
• 1438085-57-4 tert-butyl 5-(3-((4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438074-22-6 N-(4-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438074-40-8 N-(3-ethynyl-4-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438085-62-1 tert-butyl 5-(3-((4-((3-ethynyl-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438085-67-6 tert-butyl 5-(3-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438074-57-7 N-(3-ethynylphenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438085-72-3 tert-butyl 5-(3-((4-((4-bromo-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438074-75-9 N-(4-bromo-2-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 

Relevant articles and documents

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement

With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with in silico predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES

The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteoraryl carboxylic acids and certain diazabicycloalkanes. The

Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors

Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibit

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment bacterial infections in mammals, particularly humans, are disclosed herein.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloakane derivatives

Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.